$ADPT

2 stories mentioning ADPT

Every FINWIRES story that references ADPT, newest first.

Adaptive Biotechnologies Weighs Separation of Immune Medicine Unit; Shares Fall After Hours

Adaptive Biotechnologies (ADPT) is evaluating strategic and structural alternatives for its immune medicine segment in a plan to separate the business from its minimal residual disease division.A decision on the separation is expected by year-end, the company said Monday in a statement.Adaptive shares fell 5.6% in after-hours trading.

$ADPT

Insider Trading54d ago

Adaptive Biotechnologies Insider Sold Shares Worth $1,008,622, According to a Recent SEC Filing

Julie Rubinstein, President and Chief Operating Officer, on April 17, 2026, sold 69,061 shares in Adaptive Biotechnologies (ADPT) for $1,008,622. Following the Form 4 filing with the SEC, Rubinstein has control over a total of 395,146 common shares of the company, with 395,146 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1478320/000178066426000028/xslF345X05/form4.xml

$ADPT